STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug
Patient advocates and some experts are expressing growing alarm over the perceived risks of a rare disease drug sold by Neurocrine Biosciences.
Two months have passed since Neurocrine Biosciences unveiled an open letter regarding potential safety concerns surrounding their rare disease drug, Vykat XR. Patient advocates and certain experts are now expressing growing apprehension regarding the perceived risks associated with this therapy. Vykat, which is approved for treating Prader-Willi syndrome—a condition that leads to an overwhelming sensation of hunger—has been implicated in the deaths of seven individuals and the hospitalization of nearly 100 others since its approval 18 months prior.
The case reports on these fatalities and hospitalizations, which were submitted to regulatory authorities and obtained by STAT through the Freedom of Information Act, do not definitively establish a causal relationship. Nevertheless, many of the Vykat cases involved complex medical conditions and multiple medications. Some medical experts contend that the existing evidence is compelling enough to conclude that Vykat is causing undue harm. This story will continue to unfold in STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
